Latest Administration News

Indiana Resources appoints seasoned mining executive Matthew Bowles as Managing Director to spearhead expansion at its Minos Gold Project, while promoting John Fitzgerald to COO amid a strong cash position.

Pacific Edge reports steady demand for its Cxbladder cancer diagnostic tests despite losing Medicare coverage and transitioning US customers to a new test. The company is advancing clinical evidence and a $21 million capital raise to support growth and regain coverage.

Queste Communications reported a significant $3 million cash inflow in June 2025, driven by a royalty termination payment from its controlled entity, Orion Equities Limited, strengthening its liquidity position.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Imagion Biosystems has received encouraging feedback from the FDA on its planned Phase 2 HER2 breast cancer clinical trial, paving the way for its Investigational New Drug application submission later this year.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Imricor Medical Systems has secured key European regulatory approvals for its second-generation NorthStar system and initiated its commercial launch, while US FDA submissions progress amid some delays.

Netwealth Group Limited has reported a record $15.8 billion in Funds Under Administration net flows for FY25, marking a 40% increase over the previous year and pushing total FUA to $112.8 billion. The company’s strong platform growth and strategic board appointment signal continued momentum.

Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.

BlackRock Investment Management has announced the estimated distribution components for its iShares High Growth ESG ETF for the fiscal year ending June 30, 2025, highlighting a total cash distribution of 69.13 cents per unit.

A VCAT ruling has invalidated the Deferred Management Fee clause in Lifestyle Communities’ contracts due to disclosure issues, prompting an imminent appeal and contract revisions.

Argent BioPharma has begun supplying its EU-GMP cannabinoid API for drug-resistant epilepsy treatment at University Medical Centre Ljubljana, marking a key clinical and regulatory milestone in Europe.